Yang, Hyun Gul; Kang, Moon Cheol; Kim, Tae Yoon; Hwang, Injung; Jin, Hyun Tak; Sung, Young Chul; Eom, Ki-Seong; Kim, Sae Won
Journal for immunotherapy of cancer
2019May ; 7 ( 1 ) :138.
PMID : 31126350
ÀúÀÚ »ó¼¼Á¤º¸
Yang, Hyun Gul - Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk, 37673, Republic of Korea.
Kang, Moon Cheol - SL-BIGEN Inc., 700 Daewangpanyo-Ro, Bundang-Gu, Seongnam, Gyeonggi, 13488, Republic of Korea.
Kim, Tae Yoon - SL-BIGEN Inc., 700 Daewangpanyo-Ro, Bundang-Gu, Seongnam, Gyeonggi, 13488, Republic of Korea.
Hwang, Injung - SL-BIGEN Inc., 700 Daewangpanyo-Ro, Bundang-Gu, Seongnam, Gyeonggi, 13488, Republic of Korea.
Jin, Hyun Tak - SL-BIGEN Inc., 700 Daewangpanyo-Ro, Bundang-Gu, Seongnam, Gyeonggi, 13488, Republic of Korea.
Sung, Young Chul - Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk, 37673, Republic of Korea. ycsung@postech.ac.kr.
Eom, Ki-Seong - Division of Hematology, Department of Internal Medicine, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-Daero, Seocho-Gu, Seoul, 06591, Republic of Korea. dreom@catholic.ac.kr.
Kim, Sae Won - SL-BIGEN Inc., 700 Daewangpanyo-Ro, Bundang-Gu, Seongnam, Gyeonggi, 13488, Republic of Korea. swkim@slbigen.com.
ABSTRACT
BACKGROUND: Human natural killer (NK) cell lines serve as an attractive source for adoptive immunotherapy, but NK-92 remains the only cell line being assessed in the clinic. Here, we established a novel NK cell line, NK101, from a patient with extra-nodal natural killer/T-cell lymphoma and examined its phenotypic, genomic and functional characteristics.
METHODS: Single cell suspensions from lymphoma tissue were expanded with anti-NKp46/anti-CD2-coated beads in the presence of IL-2. A continuously growing CD56(+) cell clone was selected and designated as NK101. Flow cytometry and RNA sequencing were used to characterize phenotypic and genomic features of NK101. In vitro cytotoxicity and IFN-γ/TNF-α secretion were measured by flow cytometry-based cytotoxicity assay and enzyme-linked immunosorbent assay, respectively, after direct co-culture with tumor cells. Immunomodulatory potential of NK101 was assessed in an indirect co-culture system using conditioned medium. Finally, in vivo antitumor efficacy was evaluated in an immunocompetent, syngeneic 4T1 mammary tumor model.
RESULTS: NK101 displayed features of CD56(dim)CD62L(+) intermediate stage NK subset with the potential to simultaneously act as a cytokine producer and a cytotoxic effector. Comparative analysis of NK101 and NK-92 revealed that NK101 expressed lower levels of perforin and granzyme B that correlated with weaker cytotoxicity, but produced higher levels of pro-inflammatory cytokines including IFN-γ and TNF-α. Contrarily, NK-92 produced greater amounts of anti-inflammatory cytokines, IL-1 receptor antagonist and IL-10. Genome-wide analysis revealed that genes associated with positive regulation of leukocyte proliferation were overexpressed in NK101, while those with opposite function were highly enriched in NK-92. The consequence of such expressional and functional discrepancies was well-represented in (i) indirect co-culture system where conditioned medium derived from NK101 induced greater proliferation of human peripheral blood mononuclear cells and (ii) immunocompetent 4T1 tumor model where peritumoral injections of NK101 displayed stronger anti-tumor activities by inducing higher tumor-specific immune responses. In a manufacturing context, NK101 not only required shorter recovery time after thawing, but also exhibited faster growth profile than NK-92, yielding more than 200-fold higher cell numbers after 20-day culture. CONCLUSION: NK101 is a unique NK cell line bearing strong immunostimulatory potential and substantial scalability, providing an attractive source for adoptive cancer immunotherapy.
keyword
Adoptive cancer immunotherapy; Immunostimulatory potential; NK cell line; Off-the-shelf platform
¸µÅ©